Updates in Biomarker Testing in Non-Small Cell Lung Cancer
Biomarker testing is becoming more important due to the shift in cancer care to targeted therapies. Especially in NSCLC, there are many new updates in which biomarkers should be tested, when testing is required or recommended, and what the barriers are to implementing testing for all patients.
Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 2.2023

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC.

NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
Communicating Within the Interdisciplinary Care Team for NSCLC (JA copy)

This module will feature members of the NSCLC care team presenting best practice protocols for integrating biomarker testing and discussing practical challenges such as timing, sequencing versus broad panel testing, and the roles of the interdisciplinary team.

Implications of Biomarker Testing in the Era of Targeted NSCLC Therapies (JA copy)
This module will present current and new clinical data of targeted therapies and how this information translates into personalized medicine and the development of individualized treatment plans for patients with NSCLC based on expression of biomarkers.
Tissue Acquisition and Analysis (JA copy)

This module will include a review of guidelines, tissue acquisition and sample preparation, differentiating assays, specific biomarker types and subtypes, molecular and cytopathology evaluation, and tips on how to interpret lab results.

Accurate Diagnosis and Personalized Treatment of NSCLC for the Interdisciplinary Team (JA copy)
It is essential that all members of the NSCLC care team understand the necessary processes and are equipped to apply current research on genomic targets to testing for mutations/drivers in appropriate advanced NSCLC patients.
Challenging Case Review: Non-Small Cell Lung Cancer
As a result of the therapeutic advances and clinical research affecting the management of patients with non-small cell lung cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

Pages

Subscribe to RSS - Lung Cancers